Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 11,280 Shares of Stock

Key Points

• CAO Michael Megna sold 11,280 shares at an average of $98.54, worth about $1.11 million, under a pre-arranged Rule 10b5-1 plan. He retained 12,697 shares after the sale, a 47.05% reduction in his ownership.
• Kiniksa reported quarterly EPS of $0.56, beating the $0.37 analyst consensus, and revenue of $285.97 million versus estimates of $260.66 million.
• Analysts maintain a “Moderate Buy” consensus with a $100.57 average price target; shares recently traded at $96.28, near their one-year high of $99.31.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 11,280 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $98.54, for a total value of $1,111,531.20. Following the completion of the sale, the chief accounting officer directly owned 12,697 shares in the company, valued at $1,251,162.38. This represents a 47.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 0.5%

KNSA stock traded up $0.52 during mid-day trading on Thursday, reaching $96.28. The company had a trading volume of 368,716 shares, compared to its average volume of 705,367. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $99.31. The stock has a market capitalization of $7.56 billion, a P/E ratio of 74.06 and a beta of 0.07. The stock's 50-day simple moving average is $81.53 and its two-hundred day simple moving average is $62.18.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Institutional Trading of Kiniksa Pharmaceuticals International

Institutional investors have recently made changes to their positions in the stock. Curry Webb Wealth Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $29,000. Global Retirement Partners LLC lifted its position in Kiniksa Pharmaceuticals International by 315.5% in the third quarter. Global Retirement Partners LLC now owns 428 shares of the company's stock worth $32,000 after purchasing an additional 325 shares during the period. Allworth Financial LP lifted its position in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company's stock worth $29,000 after purchasing an additional 134 shares during the period. Nykredit A S bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $34,000. Finally, Jacobi Capital Management LLC bought a new position in Kiniksa Pharmaceuticals International during the 3rd quarter valued at $48,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KNSA. The Goldman Sachs Group boosted their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a "buy" rating in a research report on Wednesday, October 28th. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 28th. Finally, Citigroup increased their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Moderate Buy" and a consensus price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa's marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.